## Stock Spotlight Report Issue #9 -- September 26th, 2021 Niche Medical Robot Manufacturer Beats Market

# GMED

Globus Medical, Inc.

Important: This document is intended for informational and entertainment purposes only, please read the full disclaimer on the last page of this document.

**Bonus!** Before you read the full report, check out these other partner offers and educational opportunities...

- Don't risk your capital! <u>Trade with other people's money.</u>
- Report: Amassing Your Fortune in GOLD in 2021 & Beyond
- A Bullish Strategy For <u>A New Bull Market</u>
- He Discovered This Secret Stock Market "Vomma Zone"
- PDF: Top 5 Tech Stocks For The Rest Of 2021
- PDF: Top 5 Growth Stocks To Consider Right Now
- Charles Payne: "These 3 secrets separate you from the WS 1%"

Be sure to check out other recent issues of this report, you can download all of the past Stock Spotlight Reports on TimingResearch.com, <u>click here</u>.

Recent Issues:

- A Bet On Enhanced Power Grid Security (ENPH)
- Monthly Dividends From Business Development (PFLT)
- Technology Simulation Provider Shows Aggressive Growth (KEYS)

## TIMINGRESEARCH.COM

**STOCK SPOTLIGHT REPORT - SEPTEMBER 26th, 2021:** This new weekly report series will provide info on one exciting stock that investors may want to assess for their portfolio. This is a BETA TEST and will further develop it over time. Please send any feedback <u>HERE</u>.

You are reading Issue #009: Niche Medical Robot Manufacturer Beats Market (GMED)

Download ALL past Stock Spotlight Reports HERE.

### NYSE: GMED Globus Medical, Inc.

Globus Medical, Inc. (NYSE: GMED) is a narrowly focused "medical device manufacturer with the singular goal of improving the quality of life for patients with musculoskeletal disorders." One especially interesting device they offer is their ExcelsiusGPS system, a robotic arm for use in spinal surgery, which makes it a top innovator to watch in the robot and AI-assisted surgery field. Globus Medical was founded in 2003 and it's IPO was in 2012.

industry summary

GMED's market cap is currently around \$8 Billion, with an average daily share volume of about 450,000. The company currently pays no dividend. The stock is up about 66% over the last year (as compared to about 37% for S&P500) with growth being relatively steady.

Despite it's innovative work and good performance, GMED seems to be relatively undervalued and by the market. If you're looking for a relatively stable, innovative company with strong fundamentals and a good track record of market-beating performance, especially as interest in the field is likely to only increase over the next decade, this might be a good one to look into for your portfolio.

Read on for charts, more info about GMED, similar companies, and other relevant info.

#### 1-Year Daily GMED chart generated by <u>TradingView</u>:





#### 5-Year Weekly GMED chart generated by <u>TradingView</u>:

#### MORE INFO

GMED Website: GlobusMedical.com (detailed investor PDFs)

Sector(s): Healthcare

Industry(s): Medical Devices / Health Care Equipment & Supplies

Location: Audubon, PA, USA

Founded: 2003

IPO Date: 2012

Prominent ETFs that hold GMED:

- IHI iShares U.S. Medical Devices ETF
- ROBO ROBO Global Robotics and Automation Index ETF
- GINN Goldman Sachs Innovate Equity ETF
- HLGE Hartford Longevity Economy ETF
- IVOG Vanguard S&P Mid-Cap 400 Growth ETF

Competitors and/or related companies:

- ISRG Intuitive Surgical, Inc.
- SYK Stryker Corporation
- NUVA NuVasive, Inc.

Related videos:

- <u>\$GMED Stock Analysis</u>, should we buy Globus Medical? Musculoskeletal disorders + <u>ROBOTIC platform!</u>
- Scalp Trading GMED for 3 points per share total

#### TIMINGRESEARCH INFO

Download ALL past Stock Spotlight Reports <u>HERE</u>.

Join us for these weekly shows:

- <u>Crowd Forecast News</u> Since August 2014, the weekly CFN show has featured a discussion with 2-5 trading experts about where they think the S&P500 is headed, what they are watching for in the markets currently, and their best current trade ideas. Submit your requests for topics for the next episode <u>here</u>.
- <u>Analyze Your Trade</u> Created in partnership with <u>FollowMeTrades.com</u> in August 2017, each Tuesday at 4PM ET (plus occasional special bonus episodes), the AYT show involves surveying the audience for the top symbols that they want our guest expert of the week to analyze live. Submit your symbol requests for the next episode <u>here</u>.

Mark your calendar for the following <u>Synergy Trader events</u> - This series is a partnership created with <u>TradeOutLoud.com</u> in August 2019; for this educational series we bring together some of the world's top traders to share their secrets, tips, tricks, and tactics:

- October 20th-21st: Commodities and Cannabis
- November 16th-18th: Friendsgiving

DISCLAIMER - PLEASE READ

TimingResearch owners, guests, affiliates, and associates are real traders and investors and may hold the equities discussed in this report directly or indirectly through ETFs or other funds.

This report is for information and entertainment purposes only; trading and investing is extremely risky. We've made every reasonable attempt to ensure that the above information is accurate at the time of publication, but please do your own research. The reader bears sole responsibility for their trading and investing decisions. Please consult a qualified financial advisor for help with financial decisions.

TimingResearch may generate revenue from any link on the webiste, emails, reports, or any other content.

Statement Of Disclaimer: U.S. Government Required Disclaimer - Commodity Futures Trading Commission. Futures, option, forex and stock trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This website/email is neither a solicitation nor an offer to Buy/Sell futures, options, forex or stocks. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - Hypothetical or simulated performance results have certain limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity. Simulated trading programs in general are also subject to the fact that they are designed with the benefit of hindsight. No representation is being made that any account will or is likely to achieve profit or losses similar to those shown.